Kornimate/medical-research-clean huggingface dataset:
evaluation of a smartphone application for self-help for social anxiety

Conditions: Social Anxiety

Summary: the present study examines whether a self-help app can reduce symptoms of social anxiety disorder.

the study will test the effectiveness of a newly developed mobile app in treating patients with social anxiety. participants will be randomly assigned to one of the following groups: app use only, therapist-guided app use, and a wait-list control group. over a 12-week period, the study will examine whether mobile app use leads to significant reductions in symptoms associated with social anxiety, as well as improvements in secondary outcomes such as quality of life, depression, or psychological impairment.

Eligibility criteria:
inclusion criteria: * current diagnosis of social anxiety disorder * written informed consent before the start of the study * age: 18 to 65 years * possession of smartphone * familiarity with using smartphone apps exclusion criteria: * acute suicidality * active substance abuse or dependence * severe medical conditions (e.g., chronic cardiovascular disease) * severe depression * psychotic disorder * bipolar disorder * borderline personality disorder * current psychotherapeutic treatment * current psychopharmacological treatment * no proficient skills in the german language
tandem occlusion after emergent stenting in acute ischemic stroke

Conditions: Acute Stroke; Ischemic Stroke, Acute

Summary: in acute ischemic stroke due to tandem occlusion, the emergent stenting has recently become an endovascular treatment option combining with mechanical thrombectomy to achieve recanalization. however, the data on the beneficial endovascular management of tandem occlusion in two circulations is still limited. the purpose of our study was to compare the improvement of clinical outcome between two circulations after emergent stenting at 3 months.

the posterior circulation (about 20 - 25%) is less frequent than the anterior one in the acute ischemic stroke, but high mortality and morbidity in the acute vertebrobasilar thrombosis even successful recanalization are revealed. besides, tandem occlusion is one of the complex lesions in large vessel occlusions relating to the poor outcome, particularly in the posterior circulation. recent studies have suggested that emergent stenting could be used as an additional treatment to achieve permanent recanalization together with mechanical thrombectomy in the intracranial segments. permanent recanalization is one of the most important factors that impact patient outcomes after acute ischemic stroke. however, although there are various approaches for this lesion, the comparision of the effectiveness in the two circulations remains unclear. thus, the aims of our study were to compare baseline characteristics and clinical outcome of tandem occlusions between anterior and posterior circulation after emergent stenting in extracranial arteries.

Eligibility criteria:
inclusion criteria: * age \> 18 years old * premorbid mrs \< 2 * nihss \> 5 * aspects ≥ 5 or pc-aspects ≥ 5 exclusion criteria: * onset to treatment time \> 24 hours * loss to follow up after discharge

Keywords: thrombectomy extracranial arteries endovascular treatment antegrade approach retrograde approach
urethrocutaneous fistula rate after double dartos and single dartos tubularized incised plate urethroplasty

Conditions: Hypospadias

Summary: the subjects were divided into two groups. each group comprised 30 children. children were randomly allocated in two groups via computer generated tables. children in group-a underwent single dartos tubularized incised plate urethroplasty while those in group-b underwent double dartos tubularized incised plate urethroplasty.

in group a dartos flap is raised from foreskin of the patient and applied as a single layer after tubularization in between neourethra and skin . in group b dartos flap is raised from the foreskin of patient and divided in two equal halves.both flaps are placed as two layers in between skin and neourethra.after surgery patient is kept in ward for 10 days with stent.patient is followed up in opd on after 7th day after discharge for outcome.

Eligibility criteria:
inclusion criteria all the patients above one year of age all patients having distal and mid penile hypospadias. - exclusion criteria severe chordee previously operated cases patient with undescended testis circumcised patient -
effect of desflurane on pediatric acute respiratory distress syndrome after living donor liver transplant recipients

Conditions: Pediatric Acute Respiratory Distress Syndrome; Desflurane; Biliary Atresia

Summary: biliary atresia is a serious congenital anomaly characterized by persistent and progressive cholestatic jaundice. the incidence of biliary atresia is more common in east asia, especially china, with an incidence of 2 per 10,000 live births. liver transplantation is the only effective way to treat end-stage liver disease. however, distant organ damage, affecting the heart, brain, kidneys, lungs, and intestines, is still an important factor affecting the long-term survival of children after surgery. desflurane is a volatile anesthetic commonly used in surgery. in order to observe the effect of desflurane on the incidence of early postoperative pediatric acute respiratory distress syndrome (pards) with biliary atresia who underwent living donor liver transplantation, and explore the related mechanism, a total of 165 infant patients underwent living liver transplantation due to biliary atresia from march 2023 to october 2023 are included in our single-center prospective study. they are randomly divided into propofol group (n=55), propofol and desflurane group (n=55) and desflurane group (n=55) according to the difference of intraoperative anesthesia maintenance. gender, age, height, weight, peld scores and other preoperative basic data are recorded. operation time, anhepatic time and intraoperative blood loss volume are recorded. the basic information of liver donors are also recorded. postoperative mechanical ventilation time, icu stay time, tacrolimus concentration, total length of hospital stay and mortality during hospitalization are recorded. according to the the definition of pards recommended by the 2015 pediatric acute lung injury consensus conference is used as the diagnostic and grading criteria for postoperative pards, and the incidence and grading of pards within the first seven days after surgery are evaluated in the three groups. peripheral blood is collected immediately after anesthesia induction, 30min after reperfusion and at the end of surgery to detect serum levels of hmgb1, il-6 and tnf-α by enzyme linked immunosorbent assay (elisa).


Eligibility criteria:
inclusion criteria: * the diagnosis was biliary atresia * living donors were either the father or the mother * 3months ≤age ≤ 36 months exclusion criteria: * the preoperative diagnosis was not biliary atresia * the donor was not a parent * age \ 36 months * the patient had perinatal disease or congenital cardiopulmonary deformity * the patient had acute respiratory infection before surgery * the patient had hepatopulmonary syndrome * retransplantation

Keywords: pediatric acute respiratory distress syndrome living donor liver transplant desflurane biliary atresia
the difference between using local and general dexamethasone in arthroscopic anterior cruciate ligament repair

Conditions: ACL Injury

Summary: arthroscopic knee injuries, such as the anterior cruciate ligament (acl) injury, are common and often result in postoperative pain. regional anesthetic techniques, such as femoral nerve block (fnb) and adductor canal block (acb), can help alleviate pain and reduce opioid consumption. acb, which blocks the saphenous nerve and obturator nerve branches, is preferred over fnb due to its potential to decrease mobility and increase falls risk. dexamethasone, a potent glucocorticoid, is used as an adjuvant for acb, but its perineural administration may carry neurotoxicity risks. some pain physicians prefer intravenous administration to prolong the action of local anesthetics used in peripheral nerve blocks.


Eligibility criteria:
inclusion criteria: * patients diagnosed with acl injury; * patients in class i, ii according to american society of anesthesiologists (asa) classification. exclusion criteria: * patients free of all inclusion criteria.
dental engagement study behavior modification

Conditions: PERIODONTAL DISEASE

Summary: this is a pilot study to determine whether knowledge gained by an individual of genetic risk for severe periodontitis changes the patient's health behavior as measured by an increased frequency of their preventive dental office visits. in addition to the primary objectives of the study, the overall design and logistics will be used to inform a possible future study.

data to be analyzed in this study will be gathered through a patient questionnaire, genetic testing and tracking of preventive dental office visits. eight hundred (800) total participants will be randomly assigned to either the usual care or experimental groups. two hundred participants will be assigned to the usual care group and 600 will be assigned to the experimental group. it is anticipated that approximately 17% (\~100) of the experimental group subjects will refuse to enroll in the study, leaving a final total of approximately 500 subject in this group. within the experimental group, 125 subjects positive for the il-1 genetic test (periopredict® genetic risk test, interleukin genetics, inc., waltham, ma) will be identified and \~375 will test negative for the il-1 genetic test. the sponsor will enter the subject's dental office registration number into a master spreadsheet and randomly assign every fourth patient to the usual care group and all others will be assigned into the experimental group. information about the study and informed consent will be made available by the dental office for the specific groups, either by directing to a website location with videos and icfs, or alternatively by by dental office showing informational videos on provided tablet and gathering signed hardcopy icfs at schedule first visit.

Eligibility criteria:
inclusion criteria: * all adult (18 years of age or older) patients from multi-site, practice-based research network dental offices who have dental insurance coverage for preventive care twice per year, but have only used the benefit once per year in the past 2-3 years. exclusion criteria: * patients who previously have had an il-1 dental genetic test. * patients who have been diagnosed with periodontal disease.

Keywords: behavior modification genetic testing risk management oral health care
a global approach to tackle cognitive decline

Conditions: Dementia

Summary: the number of people suffering from dementia in asia (22.9 million) is more than twice the numbers in europe (10.5 million) or the americas (9.4 million), as recorded in the global impact of dementia in the world alzheimer report 2015.1 this dementia tsunami will continue to rise and the estimated number is 67 million in 2050 in asia alone, which will be 2 to 3 times higher than the estimates for europe (19 million) or the americas (30 million). devising and implementing preventive strategies against dementia is of paramount importance. the proposed project will be able to establish the associations between vrfs and cognition across cohorts with cultural, ethnical, and demographical variations. this study will generate data for evidence-based knowledge for globally implementable and effective preventive strategies for cognitive impairment and dementia.

participants will be retrospectively selected from a hong kong chinese cohort, a singaporean cohort, a british cohort, two european cohorts, and an australian cohort. subjects from the above listed cohorts who fit the study criteria will be selected for this study. demographical information, clinical, vascular risk factors, mri images and cognitive data will be retrieved from the cohorts.

Eligibility criteria:
inclusion criteria: 1. elderly community-dwelling individuals aged over 60 years old; 2. those with at least 2 time points of detailed cognitive measurements, with 2-3 years of assessment interval; 3. with at least 1 timepoint of mri (t1, flair, and dti). exclusion criteria: 1. subjects with stroke, dementia, and other neurological diseases at baseline; 2. those without longitudinal cognitive data; 3. those without mri data available.
advanced hiv: outcomes for rapid art

Conditions: HIV-1-infection

Summary: ahora is designed as a single-arm, open label, non-comparative, real-world prospective, observational study evaluating the outcomes for viral control and cd4 recovery/immune reconstitution in predominantly hispanic/latinx patients of the rio grande valley (rgv) with advanced hiv who are rapidly initiated on bictegravir/emtricitabine/tenofovir alafenamide (biktarvy) at valley aids council (vac) dba westbrook clinic (wbc). this research will help to fill data gaps still present for biktarvy in a rapid start setting among an hispanic/latinx population, including those with advanced hiv.

vac is the primary provider of hiv prevention, education and testing services and the only ryan white funded agency providing medical care and supportive services for people with hiv in the rgv. vac provides services to over 1700 patients with hiv, 52% of patients at vac are diagnosed with advanced hiv disease. generally speaking, hiv clinical trials have often lacked representation and enrollment of patients of hispanic/latinx ethnicity, and those with advanced hiv and this study has the potential to fill in those data gaps. for ahora, data from art-naive, newly diagnosed hiv-1+ adults (18 years of age and older) with late presentation (cd4\<200 or diagnosed opportunistic infection/aids-defining illness) initiated on biktarvy within 7 days from diagnosis will be collected and analyzed. patients will be enrolled through vac's linkage to care and rapido (rapid start) programs. patients appropriate for rapid art initiation with biktarvy will be recruited, with a goal of 50 enrollees. patients who agree to participate will have data collected at weeks 1,4,12, 24, 36, and 48 weeks for evaluation of time to viral suppression and efficacy, as well as evaluation of cd4 cell recovery.

Eligibility criteria:
inclusion criteria: * art-naive adults,18 years of age and older * diagnosed with hiv within 7 days of study entry * diagnosis of advanced hiv: clinical (diagnosed opportunistic infection/aids-defining illness) or laboratory (cd4\<200) diagnosis of advanced hiv. exclusion criteria: * known severe renal impairment (crcl \<30 ml/min/1.73 m2); * known or suspected severe hepatic impairment or unstable liver disease (child pugh class c); * use of rifamycins for treatment of ois * use of concomitant medications that would be contraindicated for coadministration with biktarvy; * oi diagnosis requiring initiation of oi treatment for \>7 days prior to initiation of art. * pregnant at time of diagnosis

Keywords: rapid start rapid art initiation bictegravir hispanic latinx latinos advanced hiv aids
partosure to predict spontaneous preterm delivery in pregnancies after assisted reproductive technology (art)

Conditions: Infertility

Summary: to calculate sensitivity (sn), specificity (sp), positive predictive value (ppv) and negative predictive value (npv) of partosure ttd test in predicting delivery within 7 or 14 days from testing and to compare it with cervical length (cl) measurement by transvaginal ultrasound (15 mm cut-off)

* this trial is a prospective observational study. * pregnancies after art between 20 0/7 and 36 6/7 weeks with symptoms of preterm labor, clinically intact membranes, cervical dilatation of ≤ 2 cm will be invited to participate to the study. signed consent form is required to be able to participate to the study. * partosure and cl will be performed on all patients and the test-to-spontaneous-delivery interval will be calculated. * trial population:pregnancies after art between 20 0/7 and 36 6/7 weeks with symptoms of preterm labor are hospitalized at my duc hospital from october 2015 to april 2016. the sample size for this trial of 100 subjects.

Eligibility criteria:
inclusion criteria: to be eligible for enrollment into this trial, each female subject must fulfill all of the following criteria at the start of enrollment: * pregnancies after assisted reproductive technology include singleton and twins * between 20 0/7 and 36 6/7 weeks with symptoms of preterm labor including uterine contractions, intermittent lower abdominal pain and pelvic pressure. * clinically intact membranes. * cervical dilatation of ≤ 2 cm * agree to participate in the study, and to disclose any medical events to the investigator * have given written informed consent exclusion criteria: to be eligible for enrollment in this study each subject must not meet any of the following criteria: * vaginal bleeding * overt rupture of the fetal membranes as indicated by visualized leakage of fluid from the cervix * placenta previa * cervical cerclage in place * received tocolytic medications for treatment of threatened preterm delivery prior to collection of the cervicovaginal specimens or cl measurement. * digital exam prior to specimen collection. * a symptom not associated with idiopathic threatened preterm delivery (e.g trauma) * enrollment in a tocolytic study.

Keywords: partosure ttd test cl art sn sp ppv npv
open label study of zonisamide in the treatment of epilepsy in patients with mental retardation

Conditions: Epilepsy; Mental Retardation; Developmental Disabilities

Summary: the purpose of this study is to assess the efficacy and tolerability in "real-world" clinical practice, of adjunctive zonisamide treatment in adult patients with developmental disabilities and epilepsy.

while a number of randomized double-blind controlled trials have demonstrated the value of zonisamide in the treatment of seizures, such studies lend limited insight into the efficacy and tolerance of zonisamide in real-world clinical practice. furthermore, randomized trials tend to inquire about negative effects, such as adverse reactions, while positive effects such as improvement in mood, or sense of well-being are not similarly categorized. in addition, there is little information about experience with zonisamide specifically in adult patients with mental retardation (mr) / developmental disabilities (dd). anecdotal experience suggests that zonisamide is exceptionally well-tolerated, and is associated with an improved general sense of well-being and quality of life in non-dd patients. in patients with mr/dd, observational studies that promote awareness of such distinguishing features and other aspects of efficacy are essential for guiding decision-making when prescribing antiepileptic drugs.

Eligibility criteria:
inclusion criteria: * male or female, at least 18 years of age * diagnosis of mental retardation * uncontrolled seizures or intolerable side effects from current aeds * legal guardian is able to consent exclusion criteria: * sulfa allergy * prior exposure to zonisamide

Keywords: epilepsy mental retardation developmental disabilities
navigator-assisted hypofractionation (navah) on radiation therapy completion in breast cancer and prostate cancer

Conditions: Breast Cancer; Prostate Cancer

Summary: the purpose of this clinical trial is to evaluate radiation therapy (rt) completion rates among underrepresented cancer populations using qualitative measurements. additionally, the study aims to assess the impact of patient navigators on supporting patients through their radiation care, as well as their influence on adherence to standard of care treatment modalities.

the study aims to utilize qualitative measurements, including pre- and post-treatment breast and prostate cancer surveys tailored to specific ethnic groups-native american, african american, and hispanic/latino populations. in addition to these culturally relevant surveys, participants will also complete the cost-functional assessment of chronic illness therapy (cost-fact) score to evaluate the financial and functional impact of their cancer care experience. those who choose to complete the surveys will be offered navigation assistance as part of the study intervention.

Eligibility criteria:
inclusion criteria: * subjects must have histologically or cytologically confirmed breast or prostate cancer. * subjects must be 18 years of age or older. this study requires informed consent by the subject. * subjects must be of african american race, native american race, or hispanic ethnicity. * subjects scheduled to undergo rt for cancer treatment. * subjects must have the ability to understand and the willingness to sign a written informed consent document. exclusion criteria: * subjects not of african american race, native american race or hispanic ethnicity. * subjects without histologically/cytologically confirmed breast or prostate cancer. * subjects younger than 18 years old.

Keywords: native american (na)
coaching and activity tracking in multiple sclerosis - a pilot study

Conditions: Multiple Sclerosis

Summary: the purpose of this 12-week, exploratory pilot clinical trial is to continuously and remotely assess a triad of bothersome multiple sclerosis (ms) symptoms (bam: bladder, ambulation, mood) and test the benefit of proactively treating these symptoms according to an evidence-based, multi-disciplinary, personalized protocol.

ms is a chronic, debilitating disease of the central nervous system affecting approximately 2 million people worldwide and more than 400,000 individuals in the us. ms is the most common cause of non-traumatic neurological disability in young adults. symptoms typically first afflict individuals during the prime of their professional and reproductive lives, between the ages of 20 and 40. many affected individuals are unemployed, physically disabled, and at high risk for social isolation. while disease-modifying therapies (dmts) can significantly reduce accumulation of disability in ms, patients still experience symptoms across a range of functional domains. symptoms can include problems with bladder, walking, and mood (depression and anxiety). often, these symptoms are only partially evaluated during routine ms clinic visits, and the long interval between clinic visits can result in them not being optimally managed. the goal of the current study is to pilot a system of proactively monitoring a combination of symptoms (bladder, ambulation and mood) using an activity monitor and a smartphone. adult patients with ms who are experiencing symptoms in at least 2 of the 3 domains (bladder, ambulation, mood) will be enrolled. visits will be at baseline (can be same day as routine visit to the ms clinic), and 3 months. short surveys (\<3 minutes to complete) will occur weekly, and longer surveys will occur at baseline, 6 weeks and 3 months. fitbit activity monitors will be worn for the entire 3 months.

Eligibility criteria:
inclusion criteria: * any individual above the age of 18 with a confirmed diagnosis of ms * access to a smartphone * access to wi-fi at home * able to walk (including with a cane or walker) * willing to fill out surveys at multiple time points exclusion criteria: * clinician's assessment of cognitive, dexterity, or visual impairment limiting ability to use a smartphone and subsequent technologies required by the study * inability to walk

Keywords: activity mood